Robert Lasser Email

VP . Sage Therapeutics

Current Roles

Employees:
768
Revenue:
$97.7M
About
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage's lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
Sage Therapeutics Address
215 First Street
Cambridge, MA
United States

Past Companies

Noema PharmaChief Medical Officer
Sage TherapeuticsPharmaceutical Executive/Medication Development, Access, Commercializatio
Medday PharmaceuticalsChief Medical Officer

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.